Follow the 인바이오 stock price and the full directors' dealings record of the company, a listed issuer based in South Korea. Shares are quoted on the KR market, under the authority of DART (FSS). Operating in the Chemicals sector, 인바이오 has logged 57 public disclosures. Market capitalisation: €22.1bn. The latest transaction was reported on 21 July 2026 (Purchase). Among the most active insiders: 이혁재. Every trade is accessible without an account.
52
Insider Decl.
n/a
Thresholds
€14,430
51 ops.
Buy Volume
n/a
n/a
Sell Volume
31Σ signal
Buys €14,430n/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 14,630 of 29,057 companies
51.9
score / 100
Value
66
Quality
37
FCF yld9.2%
Earn yld4.6%
EV/EBITDA10.4x
ROE1.8%
Gross mgn35%
Net mgn3.0%
Debt/EBITDA4.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.